VERA THERAPEUTICS INC (VERA)
US92337R1014 - Common Stock
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning!
What's going on in today's after hours session
Top movers in Wednesday's after hours session
Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vera Therapeutics (NASDAQ:VERA) just reported results for the fourth quarter of...
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration...
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
Top Buys by Directors: Katabi's $5M Bet on VERA
Friday 2/2 Insider Buying Report: VERA, RBB
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
BRISBANE, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and...
Vera Therapeutics prices upsized stock offering to raise $250 million
Vera Therapeutics (VERA) announces the pricing of an upsized underwritten public offering of 8.06 million shares of its Class A common stock at a public offering price of $31.00 per share.
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and...
Vera Therapeutics up 19%, announces $200M stock offering (NASDAQ:VERA)
Biotech company Vera Therapeutics plans to launch a public offering of $200M shares, with an option for underwriters to purchase additional shares.
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and...
Vera stock surges after long-term data for lead asset (update)
Vera Therapeutics (VERA) stock climbs after long-term data from its Phase 2b ORIGIN trial for lead asset atacicept in IgA nephropathy. Read more here.